TRIAL DETAIL

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Drug:
Trial Name:
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date
Age of Trial (yrs)
Treatment Phase:
Gleevec-resistant
Drug Category:
HSP90 inhibitor
Strategy:
Destroy KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
SCRI GI 148
Sponsor:
Sarah Cannon Research Institute
Patient Contact:
Johanna Bendell, MD 1-877-691-7274 asksarah@scresearch.net Trials Info 1-877-691-7274 asksarah@scresearch.net
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:

Trial Links

Trial Results

Drug Information
LRG Story about the discovery of Hsp90 inhibitors for GIST.
 
Full text article - NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models - Jensen -2008
 
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells
 
Full text article - NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
 
AACR 2012 - HSP90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression
 

Trial Sites

Name
Address
City
State
Zip
Country
3322 West End Avenue
Nashville
TN
37203
USA
Ft. Myers
FL
33916
USA
333 Cedar St
New Haven
CT
06510
USA
1201 Fifth Avenue North
St. Petersburg
FL
33705
USA
4724 N. Davis Highway
Pensacola
FL
32503
USA
2501 N. Orange Ave.
Orlando
FL
32804
USA
2316 E. Meyer Blvd.
Kansas City
MO
64132
USA
Omaha
NB
68114
USA